首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

市場調查報告書

商品編碼

1392045

Humira 生物相似藥市場：依產品類型、適應症、配銷通路、患者年齡、地區

Humira Biosimilar Market, By Product Type (Biosimilar Humira, and Interchangeable Biosimilar Humira), By Indication, By Distribution Channel, By Patient Age, By Geography

出版日期: 2023年11月01日 | 出版商:

Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計全球humira生物相似藥市場在不久的將來將顯著成長，市場規模從2023年的7.721億美元擴大到2030年的38.714億美元，複合年成長率為25.9%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	7.721 億美元
實績資料	2018-2021	預測期	2023-2030
預測期複合年成長率	25.90%	2030年市場規模預測	38.714 億美元

圖 1. Humira 生物相似藥全球佔有率(%)，依地區分類，2023 年

Humira 是生物製藥用於治療乾癬和類風濕性關節炎等自體自體免疫疾病的生物製劑，是世界上最受歡迎的生物製藥。 Humira在部分地區的專利保護到期後，生物相似藥在安全性、有效性和品質方面是高度相似的生物製藥複製品。這些生物相似藥可能會增加競爭並導致價格下降。生物相似藥可以透過提供更經濟的治療選擇來幫助降低成本並改善患者獲得基本藥物的機會。生物相似藥已被證明與原始生物製藥一樣有效和安全，使其成為患有乾癬和類風濕性關節炎等疾病的患者的可行選擇。此外，生物相似藥的出現促進了製藥業的創新，鼓勵製造商在不影響品質的情況下開發更實惠的治療方案。這種市場競爭降低了價格，增加了患者的可近性，並最終改善了醫療保健結果。此外，生物相似藥的引入增加了患者的選擇和自主權，使患者能夠根據自己的具體需求選擇最合適且最具成本效益的治療方法。

市場動態

專利到期、成本降低、自體免疫疾病盛行率上升以及有利的法規環境是預測期內推動全球 Humira 生物相似藥市場成長的主要因素。

例如，北美引領生物相似藥採用市場，多種 Humira 生物相似藥核准和推出。該地區擁有支持採用生物相似藥、增加市場競爭並可能降低成本的法律體制和政策。

然而，複雜的監管流程、智慧財產權和專利訴訟、醫生和患者意識等預計將阻礙全球腦血管造影市場在預測期內的成長。

本研究的主要特點

本報告對全球 Humira 生物相似藥市場進行了詳細分析，並列出了以 2022 年為基準年的預測期（2023-2030）的市場規模和復合年成長率。
本報告還揭示各個區隔市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
本報告還提供有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
該報告根據公司亮點、產品系列、主要亮點、業績和策略等參數，介紹了全球 Humira 生物相似藥市場的主要企業。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
Humira 生物相似藥全球市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球 Humira 生物相似藥市場的各種策略矩陣，將有助於相關人員做出決策。

公司簡介
- Amgen Inc.
- Samsung Bioepis Co.
- Sandoz International GmbH（Novartis AG）
- Mylan NV
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences
- Biogen Inc
- AbbVie Inc
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd
- Merck &Co
- Viatris Inc.
- Alvotech
- Analysts'Views

第11章章節

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI5925

Global humira biosimilar market is projected to witness substantial growth in the near future, and the market size is expected to increase from US$ 772.1 Mn in 2023 to US$ 3,871.4 Mn by 2030, with a compound annual growth rate (CAGR) of 25.9%.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 772.1 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	25.90%	2030 Value Projection:	US$ 3,871.4 Mn

Figure 1. Global Humira Biosimilar Share (%), By Region, 2023

Humira is a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis and is the most popular biologic medication in the world. Following the expiration of patent protection for humira in some regions, biosimilars are highly similar copies of biologic medications in terms of safety, efficacy, and quality. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options. Biosimilars have been proven to be just as effective and safe as the original biologic medications, making them a viable alternative for patients with conditions like psoriasis and rheumatoid arthritis. Additionally, the availability of biosimilars promotes innovation in the pharmaceutical industry, as it encourages manufacturers to develop more affordable treatment options without compromising quality. This competition in the market can drive down prices and increase accessibility for patients, ultimately leading to improved healthcare outcomes. Furthermore, the introduction of biosimilars can also enhance patient choice and autonomy, allowing them to select the most suitable and cost-effective treatment for their specific needs.

Market Dynamics

Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment is major factors expected to drive growth of the global humira biosimilar market during the forecast period.

For instance, the market for multiple humira biosimilars has been approved and introduced in North America, which has led the way in the adoption of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.

However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper the growth of the global cerebral angiography market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global humira biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global humira biosimilar market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Rani Therapeutics Holdings, Inc., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Viatris Inc., and Alvotech.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market

Global Humira Biosimilar Market Detailed Segmentation:

By Product Type:
- Biosimilar Humira (Adalimumab)
- Interchangeable Biosimilar Humira
By Indication:
- Rheumatoid Arthritis
- Psoriasis
- Crohn's Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Other Autoimmune Conditions
By Patient Age:
- Adult Patients
- Pediatric Patients
- Geriatric Patients
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Top companies in Global Humira Biosimilar Market
- Amgen
- Samsung Bioepis Co., Ltd.
- Sandoz International GmbH (Novartis AG)
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences, Inc.
- Biogen Inc.
- AbbVie Inc.
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co., Inc.
- Viatris Inc.
- Alvotech

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Patient Age
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Patent expiration
- Cost savings
- Increasing prevalence of autoimmune diseases
- Favorable regulatory environment
Market Restraints
Market Opportunity
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers Acquisitions, and Collaborations

4. Global Humira Biosimilar Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Humira Biosimilar Market, By Product Type, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Biosimilar Humira (Adalimumab)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Interchangeable Biosimilar Humira
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Global Humira Biosimilar Market, By Indication, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Juvenile Idiopathic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Other Autoimmune Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Global Humira Biosimilar Market, By Patient Age, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Humira Biosimilar Market, By Distribution Channel, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

9. Global Humira Biosimilar Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2018 -2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/ Region, 2023-2030, (US$ Mn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Company Profiles
- Amgen Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- Samsung Bioepis Co.
- Sandoz International GmbH (Novartis AG)
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences
- Biogen Inc
- AbbVie Inc
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co
- Viatris Inc.
- Alvotech
- Analysts' Views